Trump’s 100% tariffs on drugs could cost you more at the pharmacy

President Trump authorized tariffs of up to 100% on certain imported patented medicines, with duties taking effect in 120 days for larger companies and 180 days for smaller firms; caps and carve-outs include 15% max for major economies, 20% for companies that commit to some U.S. manufacturing and 0% for those with MFN deals (tariff-free through Jan 20, 2029). The measures chiefly target smaller drugmakers and ingredient suppliers — Veda Partners estimates only ~$12B of the $274B in 2025 pharma imports would face the full 100% tariff — but could raise consumer drug costs, jeopardize smaller biotech financing and disrupt supply chains.

Analysis

Immediate market winners are likely to be large integrated pharmas with deep US manufacturing footprints and diversified revenue streams; they will see relative margin stability and optionality to capture reshoring-related contracts as suppliers reallocate capacity. Small-cap biotech issuers and standalone API/CDMO vendors that rely on fragmented offshore supply chains face concentration risk: a mid-single-digit percentage rise in COGS can force pre-revenue biotechs to reprice financings or bring forward licensing discussions, compressing equity values within 3–12 months.

Reshoring is not instantaneous — domestic sterile fill/finish and API capacity will require multi-year capex and regulatory approvals, creating a protracted tightness window. That shortage will create pricing power for incumbent US manufacturers and specialized CDMOs, while raising the probability of intermittent drug shortages and staggered product launches over 6–24 months, which in turn benefits firms that can guarantee supply to payors.

Key catalysts that will change the trajectory are legal challenges and bilateral negotiations; either can materially narrow the nominal economic hit and re-open export pathways within quarters. Offsetting these are second-order political risks: expect accelerated government incentives (grants/tax credits) for domestic capacity that partially offsets capex burdens but creates winners by skewing returns toward firms that can deploy capital quickly.

The consensus underestimates the financing shock to pre-commercial biotech cohorts and overestimates immediate patient price pass-through; payors and PBMs will absorb much near-term cost, delaying consumer impact for several quarters. That lag creates a tactical window to position for dispersion: favor balance-sheet strong pharmas and US-capacity CDMOs while selectively shorting small-cap biotech and offshore-exposed suppliers ahead of financing rounds.

Key Decisions for Investors

• Overweight MRK (3–12 month horizon): buy MRK stock sized to 2–4% of fund NAV. Rationale — defensive earnings, US manufacturing optionality and likely relative multiple expansion. Risk: regulatory price reforms or headline litigation could knock 8–12% off the position; set stop at -10% or hedge with short-dated calls.
• Pair trade (3–9 months): long MRK / short XBI (equal dollar). Expect MRK to outperform small-cap biotech by 8–20% as financing stress and COGS dispersion show up in equity prices. Risk: binary clinical/BD events in XBI constituents can spike biotech returns; cap position size to limit tail exposure to 3% NAV.
• Long US-focused CDMO/contract manufacturing exposure (6–18 months): buy TMO or other large US CDMO equities or 9–12 month call spreads to capture re-shoring volume and pricing power. Target asymmetric payoff: limited premium, upside from multi-quarter margin expansion. Risk: execution delay on capex; keep position size modest (1–3% NAV) until order-books confirm.
• Event-hedge (0–6 months): buy puts on IBB or XBI (1–3 month tenors) to protect against near-term biotech drawdown through financing cycles and tariff headlines. Aim for cost <1% NAV for hedging a 10–20% downside in the sector.
• Contrarian small opportunity (6–12 months): selectively accumulate high-quality mid-cap biopharma names with strong US manufacturing footprints and positive free cash flow, funded by trimming broad biotech beta — target 3–5 names to add 1–2% NAV total. Rationale: valuation overshoot in names that actually benefit from reshoring incentives; risk is continued sector-wide derating.